Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma

Gynecologic Oncology

Volumn 103, Issue 3, 2006, Pages 1054-1062

  Shi, Wenfang ^a   Hemminki, Akseli ^b   Bartlett, Jeffrey S ^a,c,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

AAV vector targeting; Gene therapy; Heparan sulfate proteoglycan (HSPG); Integrin; Ovarian cancer

Indexed keywords

GANCICLOVIR; PROTEOHEPARAN SULFATE; THYMIDINE KINASE;

ADENOVIRUS VECTOR; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG SENSITIZATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN FOLDING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SURFACE PROPERTY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID;

ADENOVIRIDAE; CAPSID; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PLASMIDS;

EID: 33751526246     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.06.020     Document Type: Article

References (49)

1. Liu X., Clark K., and Johnson P. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6 (Feb) (1999) 293-299
2. Clark K.R., Liu X., McGrath J.P., and Johnson P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild type viruses. Hum. Gene Ther. 10 6 (1999) 1031-1039
3. Hermonat P.L., and Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 6466-6470
4. Laughlin C.A., Cardellichio C.B., and Coon H.C. Latent infection of KB cells with adeno-associated virus type 2. J. Virol. 60 (1986) 515-524
5. Lebkowski J.S., McNally M.M., Okarma T.B., and Lerch L.B. Adeno-associated virus: a vector system for efficient introduction of DNA into a variety of mammalian cell types. Mol. Cell. Biol. 8 (1988) 3988-3996
6. McLaughlin S.K., Collis P., Hermonat P.L., and Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J. Virol. 62 (1988) 1963-1973
7. Samulski R.J., Chang L.-S., and Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63 (1989) 3822-3828
8. Teramoto S., Bartlett J.S., McCarty D., Xiao X., Samulski R.J., and Boucher R.C. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: a comparison with adenovirus vectors. J. Virol. 44 11 (1998) 8904-8912
9. Tratschin J.-D., Miller I.L., Smith M.G., and Carter B.J. Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol. Cell. Biol. 5 (1985) 3251-3260
10. Walsh C.E., Liu J.M., Xiao X., Young N.S., Nienhuis A.W., and Samulski R.J. Regulated high level expression of a human γ-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7257-7261
11. Walsh C.E., Nienhuis A.W., Samulski R.J., Brown M.G., Miller J.L., Young N.S., et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J. Clin. Invest. 94 (1994) 1440-1448
12. Russell D.W., Miller A.D., and Alexander I.E. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 8915-8919
13. Halbert C.L., Alexander I.A., Wolgamot G.M., and Miller A.D. Adeno-associated virus vectors transduce primary cells much less efficiently than immortilized cells. J. Virol. 69 3 (1995) 1473-1479
14. Song S., Morgan M., Ellis T., Poirier A., Chesnut K., Wang J., et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 95 24 (1998) 14384-14388
15. Flotte T.R., Afione S.A., Conrad C., McGrath S.A., Solow R., Oka H., et al. Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10613-10617
16. Kronenberg S., Kleinschmidt J.A., and Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2 11 (2001) 997-1002
17. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 16 (2002) 10405-10410
18. Opie S.R., Warrington Jr. K.H., Agbandje-McKenna M., Zolotukhin S., and Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77 12 (2003) 6995-7006
19. Kern A., Schmidt K., Leder C., Muller O.J., Wobus C.E., Bettinger K., et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77 20 (2003) 11072-11081
20. Shi W., Arnold G.S., and Bartlett J.S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12 14 (2001) 1697-1711
21. Shi W., and Bartlett J.S. RGD inclusion in VP3 provides adeo-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7 4 (2003) 515-525
22. Girod A., Ried M., Wobus C., Lahm H., Leike K., Kleinschmidt J., et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 [published erratum appears in Nat. Med. 1999 Dec;5 (12):1438]. Nat. Med. 5 9 (1999) 1052-1056
23. Grifman M., Trepel M., Speece P., Gilbert L.B., Arap W., Pasqualini R., et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3 6 (2001) 964-975
24. Wu P., Xiao W., Conlon T., Hughes J., M A-M, F.T., et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74 (2000 (Sep)) 8635-8647
25. Fisher K., Gao G.-P., Weitzmann M.D., DeMatteo R., Burda J.F., and Wilson J.M. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70 1 (1996) 520-532
26. Ferrari F.K., Samulski T., Shenk T., and Samulski R.J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70 5 (1996) 3227-3234
27. Duan D., Yue Y., Yan Z., Yang J., and Engelhardt J.F. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105 11 (2000) 1573-1587
28. Douar A.M., Poulard K., Stockholm D., and Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75 4 (2001) 1824-1833
29. Hansen J., Qing K., Kwon H.J., Mah C., and Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74 2 (2000) 992-996
30. Thomas C.E., Storm T.A., Huang Z., and Kay M.A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78 6 (2004) 3110-3122
31. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46 (1986) 5276-5281
32. Faulds D., and Heel R.C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39 4 (1990) 597-638
33. Lal S., Lauer U.M., Niethammer D., Beck J.F., and Schlegel P.G. Suicide genes: past, present and future perspectives. Immunol. Today 21 1 (2000) 48-54
34. Hemminki A., Dmitriev I., Liu B., Desmond R.A., Alemany R., and Curiel D.T. Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res. 61 17 (2001) 6377-6381
35. Kanerva A., Zinn K.R., Chaudhuri T.R., Lam J.T., Suzuki K., Uil T.G., et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 8 3 (2003) 449-458
36. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 (1977) 59-74
37. Clark K., Voulgaropoulou F., and Johnson P. A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3 (1996 (Dec)) 1124-1132
38. Clark K., Voulgaropoulou F., Fraley D., and Johnson P. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6 (1995 (Oct)) 1329-1341
39. Summerford C., and Samulski R.J. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat. Med. 5 5 (1999)
40. Zolotukhin S. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (1999) 973-985
41. van de Loosdrecht A.A., Beelen R.H., Ossenkoppele G.J., Broekhoven M.G., and Langenhuijsen M.M. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods 174 1-2 (1994) 311-320
42. Xiao W., Warrington Jr. K.H., Hearing P., Hughes J., and Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76 22 (2002) 11505-11517
43. Summerford C., Bartlett J.S., and Samulski R.J. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5 1 (1999) 78-82
44. Carreiras F., Denoux Y., Staedel C., Lehmann M., Sichel F., and Gauduchon P. Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol. Oncol. 62 2 (1996) 260-267
45. Liapis H., Adler L.M., Wick M.R., and Rader J.S. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum. Pathol. 28 4 (1997) 443-449
46. Yan Z., Zak R., Luxton G.W., Ritchie T.C., Bantel-Schaal U., and Engelhardt J.F. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76 5 (2002) 2043-2053
47. Davies E.J., Blackhall F.H., Shanks J.H., David G., McGown A.T., Swindell R., et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 10 15 (2004) 5178-5186
48. Qiu J., Handa A., Kirby M., and Brown K.E. The interaction of heparin sulfate and adeno-associated virus 2. Virology 269 1 (2000) 137-147
49. Li E., Brown S.L., Stupack D.G., Puente X.S., Cheresh D.A., and Nemerow G.R. Integrin alpha(v)beta1 is an adenovirus coreceptor. J. Virol. 75 11 (2001) 5405-5409